Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Investa launches a rewards program giving users stock options worth up to £1,000 tied to company growth.

Company Fundamentals
11 Jun 2026
Not Specified
View Source
Bullish
pluang ai news

Investa, a UK trading app, has introduced a pioneering rewards initiative granting over 3,000 active users stock options valued up to £1,000 based on the company's £10 million valuation. This program aims to share financial benefits with users who contribute to the platform's growth, contrasting traditional models where only shareholders profit. The initiative will expand to include referral rewards, aligning user loyalty with long-term company success. Investa recently gained full FCA regulation and raised £3.6 million from investors, positioning itself as a transparent, zero-commission options trading platform for UK retail investors.

More News

Russian hacker extradited to US over Microsoft-tracked Void Blizzard cyberattacks.

Russian hacker extradited to US over Microsoft-tracked Void Blizzard cyberattacks.

A Russian national, Denis Obrezko, accused of aiding the Kremlin-linked hacking group Void Blizzard, was extradited from Thailand to the US. He faces charges related to cyber espionage targeting US and allied organizations, including at least 11 US c...

Market News
Bearish
21 hours ago
Wolters Kluwer repurchases 61,431 shares for €3.9M as part of its €500M 2026 buyback program

Wolters Kluwer repurchases 61,431 shares for €3.9M as part of its €500M 2026 buyback program

Wolters Kluwer repurchased 61,431 of its ordinary shares between June 4 and June 10, 2026, spending €3.9 million at an average price of €63.23 per share. This buyback is part of a larger €500 million program announced in February 2026, aimed at reduc...

Company Fundamentals
Bullish
22 hours ago
Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026

Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026

Oculis Holding AG announced it will present its neuroprotective drug candidate Privosegtor at the Clinical Trials at the Summit 2026 in Las Vegas. Privosegtor, designed to treat optic neuritis and other optic neuropathies, has shown promising Phase 2...

Market News
Bullish
22 hours ago
Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026

Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026

Oculis Holding AG announced it will present the development of Privosegtor, a potential first neuroprotective therapy for optic neuritis, at Clinical Trials at the Summit 2026 in Las Vegas. Privosegtor has shown promising Phase 2 results and received...

Market News
Bullish
22 hours ago
Intellistake marks one year with AI contracts, validator operations, and new Austen AI platform launch.

Intellistake marks one year with AI contracts, validator operations, and new Austen AI platform launch.

Intellistake Technologies Corp. celebrates its first year as a decentralized AI and blockchain company, achieving operational milestones including enterprise AI contracts, validator infrastructure on a decentralized network, and launching the Austen ...

Market News
Bullish
23 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App